From economics to health outcomes: Delving into the significance of reduced insulin prices
The recent substantial price reductions in insulin therapy by major manufacturers prompt an examination of their impact on South Africa (SA)’s healthcare. While Eli Lilly, Novo Nordisk, and Sanofi cut prices on long-acting basal insulin, among others, significantly, these insulins are not on SA...
Saved in:
| Main Authors: | M Leuschner, M Strydom, V Steenkamp |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
South African Medical Association
2024-08-01
|
| Series: | South African Medical Journal |
| Subjects: | |
| Online Access: | https://samajournals.co.za/index.php/samj/article/view/2014 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pediatric formulations in national essential medicines lists: a cross-sectional study
by: Camila Heredia, et al.
Published: (2025-05-01) -
Pakistan’s first medicine price deregulation policy: assessing its impact on prices, affordability, and availability of oral anti-diabetic medicines in private pharmacies
by: Amna Saeed, et al.
Published: (2025-07-01) -
Analysis of organizational and medical documents and formulary lists regulating medical support of pregnant women
by: M. L. Syatynya, et al.
Published: (2012-12-01) -
Trends and disparity in the provision and consumption of essential medicines in China from 2016 to 2021: institutional, regional, and economic variations
by: Mingyue Zhao, et al.
Published: (2025-06-01) -
Is the United States ready for Universal Healthcare?
by: Fardin Quazi, et al.
Published: (2025-08-01)